Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics (NQ: CRDL )

1.525 -0.035 (-2.24%)
Streaming Delayed Price Updated: 2:10 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cardiol Therapeutics

< Previous 1 2 3 Next >
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
Via Benzinga
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
Via AB Newswire
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially... 
Via Newsfile
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
Via AB Newswire
Topics Electric Vehicles
Exposures Electric Vehicles Product Safety
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
Via AB Newswire
Exposures Product Safety
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today
Cardiol Therapeutics shares are trading lower by 20% Wednesday morning. The company announced a $13.5 million public offering. 
Via Benzinga
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
Via AB Newswire
Topics Government
Exposures Political
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
Via AB Newswire
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
“Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…”
Via AB Newswire
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... 
Via TheNewswire.com
Exposures Product Safety
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients 
Via News Direct
Exposures Product Safety
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce... 
Via Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Exposures Product Safety
Sector Spotlight: Orphan Drug Developers With Significant Upside
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record... 
Via TheNewswire.com
Topics ETFs
Exposures Product Safety
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
Via AB Newswire
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics 
Via News Direct
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
CRDL stock results show that Cardiol Therapeutics met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)... 
Via Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)... 
Via Newsfile
Exposures Product Safety
Cardiol Therapeutics - This Penny Stock Is An Analysts Favorite
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies. 
Via Talk Markets
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a... 
Via Newsfile
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Via Get News
Topics Death
Exposures Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
--News Direct-- 
Via News Direct
Topics Death
Exposures Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Toronto, ON, October 13, 2013 (PlatoData via 500NewsWire) -- In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary... 
Via TheNewswire.com
Topics Death
Exposures Death
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback